DNA Synthesis Market Share, Size, Trends, Industry Analysis Report, 2026 - 2034
REPORT DETAILS
DNA Synthesis Market Summary
The global DNA synthesis market size was valued at USD 4.26 billion in 2025, growing at a CAGR of 16.85% from 2026 to 2034. DNA synthesis demand is fuelled by biopharma expansion and increased utilization of AI and automation in workflows.
Market Statistics
Key Takeaways
-
North America held the largest DNA synthesis market share of 42.4% in 2025, driven by strong biotech infrastructure and research funding.
-
The U.S. market is projected to grow at a CAGR of 17.1% (2026–2034), supported by rising investments in genomics and molecular biology.
-
Asia Pacific is expected to register a CAGR of 17.6% (2026–2034), fueled by genomics, vaccine development, and biotech investments.
-
The India market is anticipated to grow at a CAGR of 17.5% (2026–2034), driven by pharmaceutical expansion and stronger R&D capabilities.
-
The oligonucleotide synthesis segment accounted for the largest market share of 68.9% in 2025, owing to its widespread use in DNA synthesis workflows.
-
The therapeutics segment is expected to witness the fastest CAGR of 17.2% (2026–2034), driven by growing demand for gene therapies and precision medicine.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations
Industry Dynamics
- Biopharma development spurring use of DNA synthesis in drug development, biologics, and vaccines.
- Automation and artificial intelligence increasing efficiency, accuracy, and scalability in operations.
- Enzymatic DNA synthesis opening new avenues with scalable and faster production of long-sequences.
- Huge R&D spending constrains growth, making it difficult for smaller companies to operate smoothly.
AI Impact on DNA Synthesis Market
- AI maximizes DNA synthesis based on analysis of protocols, sequence complexity, and reagent interactions.
- AI facilitates adaptive synthesis, real-time temperature, timing, and reagent flow adjustments
- AI analysis identifies synthesis failures, reagent degradation, and contamination, minimizing waste.
- AI assists automated sequence design and workflow optimization, accelerating R&D and throughput.
The DNA synthesis market provides advanced platforms to construct DNA sequences with high accuracy, flexibility, and efficiency. It finds application in the field of pharmaceuticals, biotech, diagnostics, agriculture, and research, facilitating gene editing, synthetic biology, and the creation of new biomolecules. Chemical and enzymatic synthesis, automation, and quality control improvements are driving speed, reliability, and scalability, underpinning innovation across genomics, drug discovery, and bioengineering.
Increased genetic disorders are fueling investment in DNA synthesis for gene therapy, diagnostics, and tailored treatments. WHO estimates 10 per 1,000 individuals are afflicted, amounting to 70–80 million worldwide. Increased use of high-fidelity sequence in oncology, rare disease, and regenerative medicine is further boosting market growth.
Source: Polaris Market Research Analysis
Applications in synthetic biology are increasing gene circuits, designed microbes, and metabolic pathway design for industrial biotechnology and therapeutics. New methods in DNA synthesis, automation, and error correction permit longer, more precise sequences. Integration into research enhances development of enzymes, biomolecules, and designed biological systems in pharmaceuticals, agriculture, and bio-based industries.
Chemical DNA Synthesis vs Enzymatic DNA Synthesis
| Parameters | Chemical DNA Synthesis | Enzymatic DNA Synthesis |
| Technology Basis | Uses phosphoramidite chemistry to assemble DNA strands nucleotide by nucleotide. | Uses enzymes to synthesize DNA under biological reaction conditions. |
| Speed | Well-established and widely available but involves multiple chemical reaction and purification steps. | Potentially faster synthesis process with fewer reaction steps and streamlined workflows. |
| Accuracy | Accuracy decreases as sequence length increases, often requiring additional error correction. | Offers higher fidelity and lower error rates, particularly for longer DNA sequences. |
| Scalability | Effective for short and medium-length oligonucleotides but faces limitations with very long sequences. | Better suited for scalable production of longer and more complex DNA constructs. |
| Environmental Impact | Generates significant chemical waste and relies on hazardous solvents and reagents. | More environmentally friendly due to reduced chemical consumption and waste generation. |
| Cost Efficiency | Mature manufacturing infrastructure supports cost-effective production of standard oligonucleotides. | Costs are expected to decline as the technology matures and production scales increase. |
| Commercial Maturity | Highly established with broad commercial adoption across research and diagnostics. | Emerging technology gaining traction in synthetic biology, therapeutics, and advanced genomic applications. |
| Key Applications | PCR primers, probes, gene fragments, diagnostics, and research reagents. | Gene synthesis, synthetic biology, gene therapy development, vaccine research, and large-scale genetic engineering. |
Source: Polaris Market Research Analysis
Drivers & Opportunities
Market Driver:
Strong Growth in the Biopharmaceutical Industry Driving Utilization of DNA Synthesis in Drug Discovery, Biologics, and Vaccine Development: Global biopharma expansion is accelerating demand for DNA synthesis of gene constructs, antibody libraries, and synthetic vaccines. India's biopharma industry expanded from USD 10 billion in 2014 to USD 165.7 billion in 2024, likely to reach more than USD 300 billion by 2030. Increased investment in genomics and next-generation therapeutics brings DNA synthesis into focus as essential for speeding up pharmaceutical and healthcare development.
Market Opportunity:
Increasing Integration of Automation and AI in DNA Synthesis Workflows: Integration of automation and AI is fueling market expansion through optimized design, accuracy, and production scale-up. AI platforms identify errors, confirm sequences, and facilitate high-throughput synthesis, cutting cost and time. In October 2024, CODA platform designed synthetic DNA components with high accuracy, showcasing the role of AI in revolutionizing research, therapeutics, and synthetic biology.
mRNA Vaccines & Infectious Disease Research
DNA synthesis plays an important role in mRNA vaccine development by enabling the rapid creation of DNA templates used to produce mRNA candidates. The technology allows researchers to quickly design and test vaccine sequences against emerging infectious diseases.
Growing investments in infectious disease research and pandemic preparedness are increasing the use of synthetic DNA in vaccine discovery and development. DNA synthesis also supports rapid response efforts by helping accelerate the development of new vaccines, diagnostic tools, and genetic research programs during disease outbreaks.
Challenges in DNA Synthesis Market
- High Cost of Long Sequences: Synthesizing long and complex DNA sequences remains costly because additional synthesis and validation steps are often required.
- Error Rates in Synthesis: Errors can occur during DNA synthesis, especially as sequence length increases, creating challenges for downstream applications.
- Regulatory Complexity: DNA synthesis products used in healthcare and biotechnology must comply with different regulatory requirements across regions.
- Scalability Limitations: Scaling up production while maintaining DNA quality, accuracy, and consistency remains a challenge.
- Technical Complexity: DNA synthesis requires specialized technologies, equipment, and expertise, which can increase operational complexity for manufacturers and research organizations.
Source: Polaris Market Research Analysis
Segmental Insights
By Type
On the basis of type, the market is segmented into oligonucleotide synthesis and gene synthesis. The oligonucleotide synthesis segment accounted for the largest market share of 68.9% in 2025, owing to its extensive use in PCR assays, next-generation sequencing, molecular diagnostics, and targeted therapeutic research. Its significant application in facilitating high-throughput genetic analysis and diagnostic assays for infectious diseases, oncology, and personalized medicine made it the most used type of DNA synthesis.
The gene synthesis segment expected to growth at the highest growth rate in the forecast period, driven by its expanding use in synthetic biology, genetic engineering, vaccine development, and large-scale DNA assembly for cutting-edge therapeutics and biotechnological innovations. The segment is expanding on account of the growing need for sophisticated DNA constructs and engineered organisms that facilitate innovations in metabolic engineering, bio-based materials, and next-generation drug development.
By Application
On the basis of application, the market is divided into diagnostics, therapeutics, and research & development. The diagnostics segment led the market by 25.6% in 2025 due to the growing use of DNA-based assays, biomarker discovery, and infectious disease detection in healthcare, research, and clinical applications. Uses in early disease detection, personalized diagnosis, and precision medicine is driving up demand for high-quality synthetic DNA for precise and fast testing solutions.
The therapeutics market is projected to advance at the rapid pace over the forecast period, driven by increasing demand for gene therapies, personalized medicine, biologics, and precision therapeutics that involve the need for accurate and scalable DNA constructs. Growing emphasis on rare disease, oncology drugs, and advanced molecular therapeutics is driving adoption of DNA synthesis technologies that enables large-scale production, high-fidelity sequences, and fast turnaround times.
By End-User
On the basis of end-user, the industry is divided into pharmaceutical & biotechnology firms, contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs), and others. In 2025, the pharmaceutical & biotechnology firms segment had the largest share of 56.2%, owing to increasing use of DNA synthesis in drug discovery, gene therapy development, biologics, and research-based innovation. These businesses depend heavily on artificial DNA for the development, testing, and production of advanced therapeutic products, creating steady demand for high-quality materials.
The CROs and CDMOs segment attain the fastest growth, boosted by the worldwide trend of outsourcing DNA synthesis operations to cut costs, increase scalability, and speed up the research timeline. Growing acceptance of third-party vendors providing automated processes, precision synthesis, and tailored DNA constructs is helping small organizations, startups, and research institutions avail of advanced solutions, leading to heavy market expansion.
Source: Polaris Market Research Analysis
Regional Analysis
North America held the largest DNA synthesis market share of 42.4% in 2025, with top biotech and pharma organizations requiring personalized DNA constructs. Expansion in gene therapy, synthetic biology, and CRISPR research is fueling uptake. Government investment, private venture, and academia-industry collaborations drive innovation and commercialization.
U.S. DNA Synthesis Market Analysis
The U.S. market is projected to grow at a CAGR of 17.1% (2026–2034). The U.S. dominated North America as a result of increasing public funding in genomics and molecular biology. In September 2024, NIH granted USD 5.4 million to integrate genomics into learning health systems. Robust federal support is placing increasing demand on DNA synthesis in research and therapeutics.
Asia Pacific DNA Synthesis Market Insights
Asia Pacific is expected to register a CAGR of 17.6% (2026–2034), powered by investment in genomics, molecular diagnostics, and vaccine sectors. India, China, Japan, and South Korea's growth of research institutions and biotechnology innovation are propelling the take-up of next-generation DNA synthesis technologies.
India DNA Synthesis Market Analysis
The India market is anticipated to grow at a CAGR of 17.5% (2026–2034), driven by fast pharma growth and growing R&D. India was the third-largest volume producer of drugs in 2023 with a 20% global generic export market share. The USD 50 billion industry targets USD 450 billion by 2047, increasing DNA synthesis demand for genomics and drug discovery.
Europe DNA Synthesis Market Assessment
Europe held substantial market share in 2025, supported by state funding for genomics, biobanking, and synthetic biology. EU endeavors such as Horizon Europe and high CRISPR adoption facilitate big genomics, agricultural biotech, and bioeconomy initiatives, fueling the adoption of precise DNA synthesis.
Source: Polaris Market Research Analysis
Key Players & Competitive Analysis
The market worldwide is competitive, dominated by Twist Bioscience, DNA Script, and Molecular Assemblies. Twist increases synthetic DNA portfolios, DNA Script provides benchtop platforms for on-demand oligonucleotides, and Molecular Assemblies creates faster, more precise, and reagent-scarce DNA synthesis techniques. AI-optimized integrated platforms and high-throughput workflows decrease costs.
Major players in the market for DNA synthesis are BIONEER CORPORATION, Camena Bioscience Ltd., DNA Script SAS, Eton Bioscience, Inc., Eurofins Scientific SE, GenScript Biotech Corporation, IBA Lifesciences GmbH, Integrated DNA Technologies, Inc., LGC Biosearch Technologies Limited, Molecular Assemblies, Inc., Quintara Biosciences, Inc., Synbio Technologies, Inc., Thermo Fisher Scientific, Inc., Touchlight Genetics Ltd., and Twist Bioscience Corporation.
Key Players
- BIONEER CORPORATION
- Camena Bioscience Ltd.
- DNA Script SAS
- Eton Bioscience, Inc.
- Eurofins Scientific SE
- GenScript Biotech Corporation
- IBA Lifesciences GmbH
- Integrated DNA Technologies, Inc.
- LGC Biosearch Technologies Limited
- Molecular Assemblies, Inc.
- Quintara Biosciences, Inc.
- Synbio Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Touchlight Genetics Ltd.
- Twist Bioscience Corporation
DNA Synthesis Industry Developments
- June 2026: IDT launched end-to-end oncology research workflows integrated with Illumina software, supporting targeted cancer research and expanding its clinical diagnostics capabilities. (Source: investing.com)
- October 2025: Launched an enzymatic DNA synthesis platform with an On-Time Guarantee, delivering sequence-perfect clonal DNA up to 50 kb without complex assembly steps. (Source: chemxpert.com)
- May 2025: Ginkgo Bioworks and Twist Bioscience prolonged their partnership to three years when Ginkgo prepaid for DNA products and Twist acquired long DNA technology licenses. (Source: twistbioscience.com)
- March 2025: Integrated DNA Technologies (IDT) entered into a partnership with Elegen to offer early access to ENFINIA Plasmid DNA service for genes that are complex-sized between 5–15 kb. (Source: idtdna.com)
Future Outlook
The DNA synthesis market is expected to witness significant growth over the coming years, driven by the rapid expansion of synthetic biology and increasing adoption in gene therapy and precision medicine. Advancements in enzymatic DNA synthesis and automated synthesis technologies are improving efficiency, accuracy, and scalability across research and commercial applications.
Growing demand for personalized healthcare solutions, coupled with the rising use of DNA synthesis in vaccine development and genetic engineering, is further supporting market expansion. As biotechnology and life sciences continue to evolve, DNA synthesis is expected to remain a foundational technology enabling innovation across healthcare, agriculture, and industrial biotechnology worldwide.
DNA Synthesis Market Segmentation
By Type Outlook (Revenue, USD Billion, 2021–2034)
- Oligonucleotide Synthesis
- Gene Synthesis
By Application Outlook (Revenue, USD Billion, 2021–2034)
- Diagnostics
- Infectious Diseases
- Cancer
- Others
- Therapeutics
- Gene Therapy
- Preventive Medicine
- Others
- Research & Development
- Cloning and Gene Editing
- Drug Discovery & Development
- Others
By End-User Outlook (Revenue, USD Billion, 2021–2034)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)
- Others
By Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
DNA Synthesis Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 4.26 Billion |
| Market Size in 2026 | USD 4.96 Billion |
| Revenue Forecast by 2034 | USD 17.24 Billion |
| CAGR | 16.85% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
FAQ's
The global market size was valued at USD 4.26 billion in 2025 and is projected to grow to USD 17.24 billion by 2034.
The global market is projected to register a CAGR of 16.85%% during the forecast period.
North America held the largest DNA synthesis market share of 42.4% in 2025.
A few of the key players in the market are BIONEER CORPORATION, Camena Bioscience Ltd., DNA Script SAS, Eton Bioscience, Inc., Eurofins Scientific SE, GenScript Biotech Corporation, IBA Lifesciences GmbH, Integrated DNA Technologies, Inc., LGC Biosearch Technologies Limited, Molecular Assemblies, Inc., Quintara Biosciences, Inc., Synbio Technologies, Inc., Thermo Fisher Scientific, Inc., Touchlight Genetics Ltd., and Twist Bioscience Corporation.
The oligonucleotide synthesis segment accounted for the largest market share of 68.9% in 2025, due to its widespread application in PCR assays, next-generation sequencing, molecular diagnostics, and targeted therapeutic research.
The therapeutics segment is projected to witness the fastest growth during the forecast period, fueled by rising demand for gene therapies, personalized medicine, biologics, and precision therapeutics that require precise and scalable DNA constructs.
Download Sample Report of DNA Synthesis Market
Please fill out the form to request a customized copy of the research report.
